Choosing the best path to patients: how to decide between in-house and outsourced iPSC therapy development and manufacturing

Induced pluripotent stem cells (iPSCs) offer the potential of creating life-changing regenerative medicine products for many current unmet needs. To ensure iPSC-based therapies have the possibility to reach their breakthroughs potential, we as developers should ensure that they actually can be accessible to patients—and that means considering also the market demands of the over-burdened healthcare systems across the world. In this article, we offer some viewpoints and considerations around the accessibility of therapies from the cost perspective, debating the alternative models of development and manufacturing of iPSC-based therapies.

Please enter your email to access content Read now